Late-Onset Pompe Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Late-onset Pompe disease (LOPD, juvenile, and adult-onset) can appear as early as one year old and as late as the sixth decade. The late-onset form is associated with significant morbidity and is distinguished by progressive skeletal muscle weakness and respiratory insufficiency, eventually leading to respiratory failure and death. The late-onset form is variable, with all possible neuromuscular, musculoskeletal, respiratory, and cardiac symptoms. Muscle weakness is generally more pronounced in the proximal muscles of the lower extremities, with less involvement of the distal muscles and upper extremities. Muscle pathology can be asymmetric or symmetric; the trunk, thigh, and pelvic girdle muscles are the most likely to be affected, and specific muscle groups may be involved selectively. Patients may experience difficulty walking, running, participating in sports, climbing stairs, rising from a chair, or rising from a supine position. Motor development milestones are frequently missed in children with late-onset Pompe disease. In addition, limb-girdle weakness, back pain, fatigue, and muscle cramps are common complaints.

·       The prevalence of Late-Onset Pompe disease ranges from 1 in 50,000 people in the USA.

 

Thelansis’s “Late-Onset Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Late-Onset Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Late-Onset Pompe Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Late-Onset Pompe Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Late-Onset Pompe Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Late-Onset Pompe Disease, Late-Onset Pompe Disease market outlook, Late-Onset Pompe Disease competitive landscape, Late-Onset Pompe Disease market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)